Loading
Life sciences · Journal article
Journal of Gynecologic Oncology · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: To evaluate the real-world effectiveness of first-line niraparib maintenance therapy in Korean patients with advanced epithelial ovarian cancer (EOC) and assess outcomes across clinical and molecular subgroups.Methods: This multicenter retrospective study included patients with newly diagnosed International Federation of Gynecology and Obstetrics stage III-IV EOC who completed first-line platinum-based chemotherapy between December 2019 and October 2022 at nine tertiary institutions in South Korea.Patients were classified according to receipt of niraparib maintenance or no maintenance therapy.Propensity score matching was performed based on age, neoadjuvant chemotherapy, and BRCA mutation status.Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis and Cox proportional hazards models.Results: A total of 554 patients were included (niraparib, n=248; no maintenance, n=306).In the unmatched cohort, niraparib was associated with significantly longer PFS (p<0.001) and OS (p=0.001).After 1:1 matching, 189 pairs were analyzed.The 3-year PFS rate was higher in the niraparib group (43.1% vs 25.7%; p<0.001), as was the 3-year OS rate (86.3% vs 74.7%; p=0.005).PFS benefit was observed in both BRCA-mutated and BRCA wild-type subgroups.OS improvement was evident in the BRCA wild-type subgroup, with minimal postprogression crossover.Conclusion: First-line niraparib maintenance was associated with improved PFS regardless of BRCA status and with improved OS, particularly in BRCA wild-type patients.